Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 4/2023

07-04-2023 | Azathioprine | Case Report

Corticosteroid-refractory autoimmune hepatitis after COVID-19 vaccination: a case report and literature review

Authors: Masayuki Ueno, Hiroyuki Takabatake, Junya Itakura, Rio Fujita, Takahisa Kayahara, Youichi Morimoto, Kenji Notohara, Motowo Mizuno

Published in: Clinical Journal of Gastroenterology | Issue 4/2023

Login to get access

Abstract

Several vaccines have been developed for coronavirus disease 2019 (COVID-19) and are used worldwide. Here we report a case of severe acute hepatitis induced by COVID-19 vaccination. A 54-year-old woman received two doses of the Pfizer-BioNTech COVID-19 mRNA vaccine and an additional dose of the Moderna COVID-19 mRNA vaccine. Seven days after the third dose, she noticed fatigue, appetite loss and dark urine. Laboratory tests were consistent with severe liver injury and jaundice. Anti-smooth muscle antibody and HLA-DR4 were positive; thus, we suspected that she had autoimmune hepatitis (AIH). Intravenous methylprednisolone followed by oral prednisolone were administered. Because remission was not achieved, we performed percutaneous liver biopsy. Histologically, pan-lobular inflammation with moderate infiltration of lymphocytes and macrophages, interface hepatitis, and rosette formation were present. We regarded these findings as confirmation of the diagnosis of AIH. As she had not responded to corticosteroids, we added azathioprine. Liver biochemistry tests gradually improved, and prednisolone could be tapered without relapse of AIH. Dozens of cases of AIH after COVID-19 vaccination have been reported. Corticosteroids were effective in most cases, but some patients have died from liver failure after vaccination. This case illustrates the efficacy of azathioprine for steroid-refractory AIH induced by COVID-19 vaccination.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.PubMed Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.PubMed
3.
go back to reference Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–73.PubMed Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–73.PubMed
4.
go back to reference Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.PubMed Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.PubMed
5.
go back to reference Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.PubMedPubMedCentral Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.PubMedPubMedCentral
6.
go back to reference Camacho-Domínguez L, Rodríguez Y, Polo F, et al. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J Transl Autoimmun. 2022;5:100140.PubMedPubMedCentral Camacho-Domínguez L, Rodríguez Y, Polo F, et al. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J Transl Autoimmun. 2022;5:100140.PubMedPubMedCentral
7.
go back to reference Efe C, Kulkarni AV, Terziroli Beretta-Piccoli B, et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022;76:1576–86.PubMed Efe C, Kulkarni AV, Terziroli Beretta-Piccoli B, et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022;76:1576–86.PubMed
8.
go back to reference Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 2014;67:46–51.PubMed Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 2014;67:46–51.PubMed
9.
go back to reference Chow KW, Pham NV, Ibrahim BM, et al. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig Dis Sci. 2022;67:4574–80.PubMedPubMedCentral Chow KW, Pham NV, Ibrahim BM, et al. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig Dis Sci. 2022;67:4574–80.PubMedPubMedCentral
10.
go back to reference Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.PubMed Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.PubMed
11.
go back to reference Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res. 2005;32:250–1.PubMed Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res. 2005;32:250–1.PubMed
12.
go back to reference Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13:2088–108.PubMed Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13:2088–108.PubMed
13.
go back to reference Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191–8.PubMed Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191–8.PubMed
14.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.
15.
go back to reference Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology. 2020;72:671–722.PubMed Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology. 2020;72:671–722.PubMed
16.
go back to reference Ohira H, Takahashi A, Zeniya M, et al. Clinical practice guidelines for autoimmune hepatitis. Hepatol Res. 2022;52:571–85.PubMed Ohira H, Takahashi A, Zeniya M, et al. Clinical practice guidelines for autoimmune hepatitis. Hepatol Res. 2022;52:571–85.PubMed
17.
go back to reference Takenami T, Sakaguchi K, Nishimura M, et al. Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. Acta Med Okayama. 2001;55:341–7.PubMed Takenami T, Sakaguchi K, Nishimura M, et al. Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. Acta Med Okayama. 2001;55:341–7.PubMed
18.
go back to reference Bril F, al Diffalha S, Dean M, et al. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol. 2021;75:222–4.PubMedPubMedCentral Bril F, al Diffalha S, Dean M, et al. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol. 2021;75:222–4.PubMedPubMedCentral
20.
go back to reference Hines A, Shen JG, Olazagasti C, et al. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine. BMJ Case Rep. 2021;14: e242678.PubMedPubMedCentral Hines A, Shen JG, Olazagasti C, et al. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine. BMJ Case Rep. 2021;14: e242678.PubMedPubMedCentral
21.
go back to reference Lensen R, Netea MG, Rosendaal FR. Hepatitis C virus reactivation following COVID-19 vaccination: a case report. Int Med Case Rep J. 2021;14:573–6.PubMedPubMedCentral Lensen R, Netea MG, Rosendaal FR. Hepatitis C virus reactivation following COVID-19 vaccination: a case report. Int Med Case Rep J. 2021;14:573–6.PubMedPubMedCentral
22.
go back to reference Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, et al. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity? J Autoimmun. 2021;123: 102706.PubMedPubMedCentral Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, et al. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity? J Autoimmun. 2021;123: 102706.PubMedPubMedCentral
23.
go back to reference Vuille-Lessard É, Montani M, Bosch J, et al. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021;123: 102710.PubMedPubMedCentral Vuille-Lessard É, Montani M, Bosch J, et al. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021;123: 102710.PubMedPubMedCentral
24.
go back to reference Rocco A, Sgamato C, Compare D, et al. Autoimmune hepatitis following SARS-CoV-2 vaccine: may not be a casuality. J Hepatol. 2021;75:728–9.PubMedPubMedCentral Rocco A, Sgamato C, Compare D, et al. Autoimmune hepatitis following SARS-CoV-2 vaccine: may not be a casuality. J Hepatol. 2021;75:728–9.PubMedPubMedCentral
25.
go back to reference Rela M, Jothimani D, Vij M, et al. Auto-immune hepatitis following COVID vaccination. J Autoimmun. 2021;123: 102688.PubMed Rela M, Jothimani D, Vij M, et al. Auto-immune hepatitis following COVID vaccination. J Autoimmun. 2021;123: 102688.PubMed
26.
go back to reference Wong CY, Rios EJ. Cutaneous hypersensitivity reaction with acute hepatitis following COVID-19 vaccine. JAAD Case Rep. 2021;16:44–6.PubMedPubMedCentral Wong CY, Rios EJ. Cutaneous hypersensitivity reaction with acute hepatitis following COVID-19 vaccine. JAAD Case Rep. 2021;16:44–6.PubMedPubMedCentral
27.
go back to reference Clayton-Chubb D, Schneider D, Freeman E, et al. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J Hepatol. 2021;75:1249–50.PubMedPubMedCentral Clayton-Chubb D, Schneider D, Freeman E, et al. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J Hepatol. 2021;75:1249–50.PubMedPubMedCentral
28.
go back to reference Londoño MC, Gratacós-Ginès J, Sáez-Peñataro J. Another case of autoimmune hepatitis after SARS-CoV-2 vaccination: still casualty? J Hepatol. 2021;75:1248–9.PubMedPubMedCentral Londoño MC, Gratacós-Ginès J, Sáez-Peñataro J. Another case of autoimmune hepatitis after SARS-CoV-2 vaccination: still casualty? J Hepatol. 2021;75:1248–9.PubMedPubMedCentral
29.
go back to reference Tan CK, Wong YJ, Wang LM, et al. Autoimmune hepatitis following COVID-19 vaccination: true causality or mere association? J Hepatol. 2021;75:1250–2.PubMedPubMedCentral Tan CK, Wong YJ, Wang LM, et al. Autoimmune hepatitis following COVID-19 vaccination: true causality or mere association? J Hepatol. 2021;75:1250–2.PubMedPubMedCentral
30.
go back to reference Lodato F, Larocca A, D’Errico A, et al. An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: coincidence, autoimmunity or drug-related liver injury. J Hepatol. 2021;75:1254–6.PubMedPubMedCentral Lodato F, Larocca A, D’Errico A, et al. An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: coincidence, autoimmunity or drug-related liver injury. J Hepatol. 2021;75:1254–6.PubMedPubMedCentral
31.
go back to reference Garrido I, Lopes S, Simões MS, et al. Autoimmune hepatitis after COVID-19 vaccine: more than a coincidence. J Autoimmun. 2021;125: 102741.PubMedPubMedCentral Garrido I, Lopes S, Simões MS, et al. Autoimmune hepatitis after COVID-19 vaccine: more than a coincidence. J Autoimmun. 2021;125: 102741.PubMedPubMedCentral
32.
go back to reference Avci E, Abasiyanik F. Autoimmune hepatitis after SARS-CoV-2 vaccine: new-onset or flare-up? J Autoimmun. 2021;125: 102745.PubMedPubMedCentral Avci E, Abasiyanik F. Autoimmune hepatitis after SARS-CoV-2 vaccine: new-onset or flare-up? J Autoimmun. 2021;125: 102745.PubMedPubMedCentral
33.
go back to reference Mahalingham A, Duckworth A, Griffiths WJH. First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination. Transpl Immunol. 2022;72: 101600.PubMedPubMedCentral Mahalingham A, Duckworth A, Griffiths WJH. First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination. Transpl Immunol. 2022;72: 101600.PubMedPubMedCentral
34.
go back to reference Dumortier J. Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient. Clin Res Hepatol Gastroenterol. 2022;46:101743.PubMed Dumortier J. Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient. Clin Res Hepatol Gastroenterol. 2022;46:101743.PubMed
35.
go back to reference Zhou T, Fronhoffs F, Dold L, et al. New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis: should we be more vigilant? J Hepatol. 2022;76:218–20.PubMed Zhou T, Fronhoffs F, Dold L, et al. New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis: should we be more vigilant? J Hepatol. 2022;76:218–20.PubMed
36.
go back to reference Goulas A, Kafiri G, Kranidioti H, et al. A typical autoimmune hepatitis (AIH) case following Covid-19 mRNA vaccination. More than a coincidence? Liver Int. 2022;42:254–5.PubMed Goulas A, Kafiri G, Kranidioti H, et al. A typical autoimmune hepatitis (AIH) case following Covid-19 mRNA vaccination. More than a coincidence? Liver Int. 2022;42:254–5.PubMed
37.
go back to reference Kawasaki Y, Matsubara K, Hori M, et al. Liver injury and cytopenia after BNT162b2 COVID-19 vaccination in an adolescent. Pediatr Int. 2022;64:e15178.PubMedPubMedCentral Kawasaki Y, Matsubara K, Hori M, et al. Liver injury and cytopenia after BNT162b2 COVID-19 vaccination in an adolescent. Pediatr Int. 2022;64:e15178.PubMedPubMedCentral
38.
go back to reference Hasegawa N, Matsuoka R, Ishikawa N, et al. Autoimmune hepatitis with history of HCV treatment triggered by COVID-19 vaccination: case report and literature review. Clin J Gastroenterol. 2022;15:791–5.PubMedPubMedCentral Hasegawa N, Matsuoka R, Ishikawa N, et al. Autoimmune hepatitis with history of HCV treatment triggered by COVID-19 vaccination: case report and literature review. Clin J Gastroenterol. 2022;15:791–5.PubMedPubMedCentral
39.
go back to reference Lasagna A, Lenti MV, Cassaniti I, et al. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy. 2022;14:915–25.PubMed Lasagna A, Lenti MV, Cassaniti I, et al. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy. 2022;14:915–25.PubMed
40.
go back to reference Palla P, Vergadis C, Sakellariou S, et al. Letter to the editor: autoimmune hepatitis after COVID-19 vaccination: a rare adverse effect? Hepatology. 2022;75:489–90.PubMed Palla P, Vergadis C, Sakellariou S, et al. Letter to the editor: autoimmune hepatitis after COVID-19 vaccination: a rare adverse effect? Hepatology. 2022;75:489–90.PubMed
41.
go back to reference Erard D, Villeret F, Lavrut PM, et al. Autoimmune hepatitis developing after COVID 19 vaccine: presumed guilty? Clin Res Hepatol Gastroenterol. 2022;46:101841.PubMed Erard D, Villeret F, Lavrut PM, et al. Autoimmune hepatitis developing after COVID 19 vaccine: presumed guilty? Clin Res Hepatol Gastroenterol. 2022;46:101841.PubMed
42.
go back to reference Zin Tun GS, Gleeson D, Al-Joudeh A, et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J Hepatol. 2022;76:747–9.PubMed Zin Tun GS, Gleeson D, Al-Joudeh A, et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J Hepatol. 2022;76:747–9.PubMed
43.
go back to reference Ghorbani H, Rouhi T, Vosough Z, et al. Drug-induced hepatitis after Sinopharm COVID-19 vaccination: a case study of a 62-year-old patient. Int J Surg Case Rep. 2022;93:106926.PubMedPubMedCentral Ghorbani H, Rouhi T, Vosough Z, et al. Drug-induced hepatitis after Sinopharm COVID-19 vaccination: a case study of a 62-year-old patient. Int J Surg Case Rep. 2022;93:106926.PubMedPubMedCentral
44.
go back to reference Nyein CM, Liew ZHS, Leow WQ, et al. Severe de novo liver injury after Moderna vaccination: not always autoimmune hepatitis. J Hepatol. 2022;77:556–8.PubMedPubMedCentral Nyein CM, Liew ZHS, Leow WQ, et al. Severe de novo liver injury after Moderna vaccination: not always autoimmune hepatitis. J Hepatol. 2022;77:556–8.PubMedPubMedCentral
45.
go back to reference Kang SH, Kim MY, Cho MY, et al. Autoimmune hepatitis following vaccination for SARS-CoV-2 in Korea: coincidence or autoimmunity? J Korean Med Sci. 2022;37:e116.PubMedPubMedCentral Kang SH, Kim MY, Cho MY, et al. Autoimmune hepatitis following vaccination for SARS-CoV-2 in Korea: coincidence or autoimmunity? J Korean Med Sci. 2022;37:e116.PubMedPubMedCentral
46.
go back to reference Pinazo-Bandera JM, Hernández-Albújar A, García-Salguero AI, et al. Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon? Gastroenterol Rep. 2022;10:goac014. Pinazo-Bandera JM, Hernández-Albújar A, García-Salguero AI, et al. Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon? Gastroenterol Rep. 2022;10:goac014.
47.
go back to reference López Romero-Salazar F, Veras Lista M, Gómez-Domínguez E, et al. SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger? Rev Esp Enferm Dig. 2022;114:567–8.PubMed López Romero-Salazar F, Veras Lista M, Gómez-Domínguez E, et al. SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger? Rev Esp Enferm Dig. 2022;114:567–8.PubMed
48.
go back to reference Boettler T, Csernalabics B, Salié H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77:653–9.PubMedPubMedCentral Boettler T, Csernalabics B, Salié H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77:653–9.PubMedPubMedCentral
49.
go back to reference Hermida Pérez B, Robles Gaitero S, García LR. AMA-positive hepatitis induced by the SARS-CoV-2 vaccine. Rev Esp Enferm Dig. 2022;114:297–8.PubMed Hermida Pérez B, Robles Gaitero S, García LR. AMA-positive hepatitis induced by the SARS-CoV-2 vaccine. Rev Esp Enferm Dig. 2022;114:297–8.PubMed
50.
go back to reference Cao Z, Gui H, Sheng Z, et al. Letter to the editor: exacerbation of autoimmune hepatitis after COVID-19 vaccination. Hepatology. 2022;75:757–9.PubMed Cao Z, Gui H, Sheng Z, et al. Letter to the editor: exacerbation of autoimmune hepatitis after COVID-19 vaccination. Hepatology. 2022;75:757–9.PubMed
51.
go back to reference Suzuki Y, Kakisaka K, Takikawa Y. Letter to the editor: autoimmune hepatitis after COVID-19 vaccination: Need for population-based epidemiological study. Hepatology. 2022;75:759–60.PubMed Suzuki Y, Kakisaka K, Takikawa Y. Letter to the editor: autoimmune hepatitis after COVID-19 vaccination: Need for population-based epidemiological study. Hepatology. 2022;75:759–60.PubMed
52.
go back to reference Fimiano F, D’Amato D, Gambella A, et al. Autoimmune hepatitis or drug-induced autoimmune hepatitis following Covid-19 vaccination? Liver Int. 2022;42:1204–5.PubMedPubMedCentral Fimiano F, D’Amato D, Gambella A, et al. Autoimmune hepatitis or drug-induced autoimmune hepatitis following Covid-19 vaccination? Liver Int. 2022;42:1204–5.PubMedPubMedCentral
53.
go back to reference Brubaker JED, Casaccio CL, Brazeau MJ. Recurrence of autoimmune hepatitis after COVID-19 vaccination. Cureus. 2022;14:e25339.PubMedPubMedCentral Brubaker JED, Casaccio CL, Brazeau MJ. Recurrence of autoimmune hepatitis after COVID-19 vaccination. Cureus. 2022;14:e25339.PubMedPubMedCentral
54.
go back to reference Mekritthikrai K, Jaru-Ampornpan P, Komolmit P, et al. Autoimmune hepatitis triggered by COVID-19 vaccine: the first case from inactivated vaccine. ACG Case Rep J. 2022;9:e00811.PubMedPubMedCentral Mekritthikrai K, Jaru-Ampornpan P, Komolmit P, et al. Autoimmune hepatitis triggered by COVID-19 vaccine: the first case from inactivated vaccine. ACG Case Rep J. 2022;9:e00811.PubMedPubMedCentral
55.
go back to reference Barary M, Sharifi-Razavi A, Rakhshani N, et al. Fulminant hepatitis following COVID-19 vaccination: a case report. Clin Case Rep. 2022;10:e6066.PubMedPubMedCentral Barary M, Sharifi-Razavi A, Rakhshani N, et al. Fulminant hepatitis following COVID-19 vaccination: a case report. Clin Case Rep. 2022;10:e6066.PubMedPubMedCentral
56.
go back to reference Codoni G, Kirchner T, Engel B, et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2022;5:100605.PubMedPubMedCentral Codoni G, Kirchner T, Engel B, et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2022;5:100605.PubMedPubMedCentral
57.
go back to reference Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.PubMedPubMedCentral Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.PubMedPubMedCentral
58.
go back to reference Wong CKH, Mak LY, Au ICH, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77:1339–48.PubMedPubMedCentral Wong CKH, Mak LY, Au ICH, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77:1339–48.PubMedPubMedCentral
Metadata
Title
Corticosteroid-refractory autoimmune hepatitis after COVID-19 vaccination: a case report and literature review
Authors
Masayuki Ueno
Hiroyuki Takabatake
Junya Itakura
Rio Fujita
Takahisa Kayahara
Youichi Morimoto
Kenji Notohara
Motowo Mizuno
Publication date
07-04-2023
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 4/2023
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01794-x

Other articles of this Issue 4/2023

Clinical Journal of Gastroenterology 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.